Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: GOG 0258 A RANDOMIZED PHASE III TRIAL OF CISPLATIN AND TUMOR VOLUME DIRECTED IRRADIATION FOLLOWED BY CARBOPLATIN AND PACLITAXEL VS. CARBOPLATIN AND PACLITAXEL FOR OPTIMALLY DEBULKED, ADVANCED ENDOMETRIAL CARCINOMA

 


GOG 0258 A RANDOMIZED PHASE III TRIAL OF CISPLATIN AND TUMOR VOLUME DIRECTED IRRADIATION FOLLOWED BY CARBOPLATIN AND PACLITAXEL VS. CARBOPLATIN AND PACLITAXEL FOR OPTIMALLY DEBULKED, ADVANCED ENDOMETRIAL CARCINOMA


Trial Focus

Female Reproductive Cancer

Objective

         This is a clinical trial of Cisplatin (that will be administered by I), plus radiation therapy, followed by Carboplatin and Paclitaxel (that will be administered by IV), and is standard of care, compared to Carboplatin and Paclitaxel (that will be adminis

IRB Protocol #

09-1010

Trial Status

Archived

Principle Investigator

SUSAN DAVIDSON

Sponsor

GOG

Contact

REBECCA KISSANE at (720)848-7202 or REBECCA.KISSANE@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period(s) that can last up to 6 months. A follow up period that will consist of clinic visits, physician contact, and phone contact. // Eligibility criteria include but are not limited to 18 years or older with endometrial cancer that has spread outside of the uterus, but it is still contained in the abdomen.Eligibility criteria include but are not limited to 18 years or older with endometrial cancer that has spread outside of the uterus, but it is still contained in the abdomen.